Oregon Health & Science University

Southern Research Institute

The University of Texas System

Washington University

Jessica Lee Smith

Corinne E Augelli-Szafran

Ashish Kumar Pathak

Alec Jay Hirsch

Michael S Diamond

Daniel Streblow

Nicole Haese

Omar Moukha-Chafiq

Larry D Bratton

Pei Yong Shi

Theresa Ha Nguyen

Shuklendu D Karyakarte

Baoling Ying

The present disclosure is concerned with 6-aza-nucleoside prodrugs that are capable of inhibiting a viral infection and methods of treating viral infections such as, for example, human immunodeficiency virus (HIV), human papillomavirus (HPV), chicken pox, infectious mononucleosis, mumps, measles, rubella, shingles, ebola, viral gastroenteritis, viral hepatitis, viral meningitis, human metapneumovirus, human parainfluenza virus type 1, parainfluenza virus type 2, parainfluenza virus type 3, respiratory syncytial virus, viral pneumonia, yellow fever virus, tick-borne encephalitis virus, Chikungunya virus (CHIKV), Venezuelan equine encephalitis (VEEV), Eastern equine encephalitis (EEEV), Western equine encephalitis (WEEV), dengue (DENV), influenza, West Nile virus (WNV), zika (ZIKV), Middle East Respiratory Syndromes (MERS), Severe Acute Respiratory Syndrome (SARS), and coronavirus disease 2019 (COVID-19), using these compounds. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

6-aza-nucleoside prodrugs as antiviral agents for treating virus infections

The present disclosure is concerned with xanthine analogs, methods of making xanthine analogs, and methods of treating West Nile virus using these analogs. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Xanthine analogs as potent anti-West Nile viral agents

Growing community of inventors

Beaverton, OR, United States of America

Jessica Lee Smith